Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)

FairStock Score: 40/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the business and the price. Cuprina is a $6.6 million market-cap healthcare company with just 10 employees, selling MEDIFLY sterile blowfly larvae dressings for chronic wounds and developing collagen products. That is a specialized niche, but at this scale I see no demonstrated durable moat, no pricing power proven in the numbers, and no multi-year record to judge. The financial health is poor. The stock closed at $1.90 on 2026-10-13, carrying a negative FairStock-calculated P/E of -1.33 and a P/B of 1.28. Return on equity is -1569.06% and return on capital employed is -58.90%, both FairStock calculations; debt-to-equity is 0.68. The Piotroski F-Score is 1/9 and the Altman Z-Score is 0.22, which point to severe financial distress risk. Revenue and profit growth are not available in the data, so I cannot verify a growth trajectory. The 52-week range of $0.22 to $14.80 shows extreme speculation and volatility. FairStock's score is 40/100, and its Lynch category is 'none' because only zero years of filed results are available, needing three. In Graham terms, there is no margin of safety: a positive book value multiple with deeply negative returns is not cheap, it is a speculative option on a tiny biotech. Buffett would want a durable business with predictable earnings and honest owner returns; here, the numbers show the opposite. I would need far more evidence of commercial traction, cash generation, and survivability before calling this an investment rather than a lottery ticket.

In plain English: Cuprina Holdings is a tiny healthcare company that makes medical products for chronic wounds, including sterile blowfly larvae dressings under the MEDIFLY brand and collagen dressings in development. The business looks very weak today: it is losing money, has a very small market value, and carries debt relative to its size. At $1.90 per share, the price looks expensive relative to those weak results, even though the stock has traded in a huge range over the past year.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer